| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
Riluzole is a novel neuroprotective agent that has been developed for the treatment of amyotrophic lateral sclerosis. A series of studies was undertaken to establish its pharmacokinetics on single- and multiple-dose administration in young white male volunteers. The mean absolute oral bioavailability of riluzole (50-mg tablet) was approximately 60%. Maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) values were linearly related to dose for the range studied. Cmax occurred at 1.0 hour to 1.5 hours after administration. Plasma elimination half-life appeared to be independent of dose. After repeated administration of 100 mg riluzole for 10 days, some intraindividual variability in bioavailability was seen. A high-fat meal significantly reduced the rate (tmax = 2 hours compared with 0.8 hours; Cmax = 216 ng.mL-1 compared to 387 ng.mL-1) and extent of absorption (AUC = 1,047 ng.hr.mL-1 versus 1,269 ng.hr.mL-1). With multiple-dose administration, riluzole showed dose-related absorption, although the terminal plasma half-life was prolonged slightly. Steady-state plasma concentrations were achieved within 5 days. Steady-state trough plasma concentrations were significantly higher with a 75-mg dose twice daily than with a 50-mg dose three times daily, although AUC values did not differ.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  E. V. S. Faustino and D. F. Donnelly Lamotrigine and phenytoin, but not amiodarone, impair peripheral chemoreceptor responses to hypoxia J Appl Physiol, December 1, 2006; 101(6): 1633 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. V. S. Faustino and D. F. Donnelly An important functional role of persistent Na+ current in carotid body hypoxia transduction J Appl Physiol, October 1, 2006; 101(4): 1076 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Ahn, S. E. Kim, H.-J. Jang, M.-J. Kim, D.-J. Rhie, S.-H. Yoon, Y.-H. Jo, M.-S. Kim, K.-W. Sung, and S. J. Hahn Interaction of Riluzole with the Closed Inactivated State of Kv4.3 Channels J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 323 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W-C Chen, H-H Cheng, C-J Huang, C-T Chou, S-I Liu, I-S Chen, S-S Hsu, H-T Chang, J-K Huang, and C-R Jan Effect of Riluzole on Ca2+ Movement and Cytotoxicity in Madin-Darby Canine Kidney Cells Human and Experimental Toxicology, August 1, 2006; 25(8): 461 - 469. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Buoen, O. J. Bjerrum, and M. S. Thomsen How First-Time-in-Human Studies Are Being Performed: A Survey of Phase I Dose-Escalation Trials in Healthy Volunteers Published Between 1995 and 2004 J. Clin. Pharmacol., October 1, 2005; 45(10): 1123 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. I. Kononenko, L.-R. Shao, and F. E. Dudek Riluzole-Sensitive Slowly Inactivating Sodium Current in Rat Suprachiasmatic Nucleus Neurons J Neurophysiol, February 1, 2004; 91(2): 710 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Groeneveld, H. J.M. Van Kan, S. Kalmijn, J. H. Veldink, H.-J. Guchelaar, J. H.J. Wokke, and L. H. Van den Berg Riluzole serum concentrations in patients with ALS: Associations with side effects and symptoms Neurology, October 28, 2003; 61(8): 1141 - 1143. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
